Gaspard Gerschenfeld1, Didier Smadja1, Guillaume Turc1, Stephane Olindo1, François-Xavier Laborne1, Marion Yger1, Jildaz Caroff1, Bruno Gonçalves1, Pierre Seners1, Marie Cantier1, Yann l'Hermitte1, Manvel Aghasaryan1, Cosmin Alecu1, Gaultier Marnat1, Wagih Ben Hassen1, Erwah Kalsoum1, Frédéric Clarençon1, Michel Piotin1, Laurent Spelle1, Christian Denier1, Igor Sibon1, Sonia Alamowitch1, Nicolas Chausson2. 1. From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France. 2. From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France. nicolas.chausson@chsf.fr.
Abstract
BACKGROUND AND OBJECTIVES: To investigate in routine care the efficacy and safety of IV thrombolysis (IVT) with tenecteplase prior to mechanical thrombectomy (MT) in patients with large vessel occlusion acute ischemic strokes (LVO-AIS), either secondarily transferred after IVT or directly admitted to a comprehensive stroke center (CSC). METHODS: We retrospectively analyzed clinical and procedural data of patients treated with 0.25 mg/kg tenecteplase within 270 minutes of LVO-AIS who underwent brain angiography. The main outcome was 3-month functional independence (modified Rankin Scale score ≤2). Recanalization (revised Treatment in Cerebral Ischemia score 2b-3) was evaluated before (pre-MT) and after MT (final). RESULTS: We included 588 patients (median age 75 years [interquartile range (IQR) 61-84]; 315 women [54%]; median NIH Stroke Scale score 16 [IQR 10-20]), of whom 520 (88%) were secondarily transferred after IVT. Functional independence occurred in 47% (n = 269/570; 95% confidence interval [CI] 43.0-51.4) of patients. Pre-MT recanalization occurred in 120 patients (20.4%; 95% CI 17.2-23.9), at a similar rate across treatment paradigms (direct admission, n = 14/68 [20.6%]; secondary transfer, n = 106/520 [20.4%]; p > 0.99) despite a shorter median IVT to puncture time in directly admitted patients (38 [IQR 23-55] vs 86 [IQR 70-110] minutes; p < 0.001). Final recanalization was achieved in 492 patients (83.7%; 95%CI 80.4-86.6). Symptomatic intracerebral hemorrhage occurred in 2.5% of patients (n = 14/567; 95% CI 1.4-4.1). DISCUSSIONS: Tenecteplase before MT is safe, effective, and achieves a fast recanalization in everyday practice in patients secondarily transferred or directly admitted to a CSC, in line with published results. These findings should encourage its wider use in bridging therapy. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that tenecteplase within 270 minutes of LVO-AIS increases the probability of functional independence.
BACKGROUND AND OBJECTIVES: To investigate in routine care the efficacy and safety of IV thrombolysis (IVT) with tenecteplase prior to mechanical thrombectomy (MT) in patients with large vessel occlusion acute ischemic strokes (LVO-AIS), either secondarily transferred after IVT or directly admitted to a comprehensive stroke center (CSC). METHODS: We retrospectively analyzed clinical and procedural data of patients treated with 0.25 mg/kg tenecteplase within 270 minutes of LVO-AIS who underwent brain angiography. The main outcome was 3-month functional independence (modified Rankin Scale score ≤2). Recanalization (revised Treatment in Cerebral Ischemia score 2b-3) was evaluated before (pre-MT) and after MT (final). RESULTS: We included 588 patients (median age 75 years [interquartile range (IQR) 61-84]; 315 women [54%]; median NIH Stroke Scale score 16 [IQR 10-20]), of whom 520 (88%) were secondarily transferred after IVT. Functional independence occurred in 47% (n = 269/570; 95% confidence interval [CI] 43.0-51.4) of patients. Pre-MT recanalization occurred in 120 patients (20.4%; 95% CI 17.2-23.9), at a similar rate across treatment paradigms (direct admission, n = 14/68 [20.6%]; secondary transfer, n = 106/520 [20.4%]; p > 0.99) despite a shorter median IVT to puncture time in directly admitted patients (38 [IQR 23-55] vs 86 [IQR 70-110] minutes; p < 0.001). Final recanalization was achieved in 492 patients (83.7%; 95%CI 80.4-86.6). Symptomatic intracerebral hemorrhage occurred in 2.5% of patients (n = 14/567; 95% CI 1.4-4.1). DISCUSSIONS: Tenecteplase before MT is safe, effective, and achieves a fast recanalization in everyday practice in patients secondarily transferred or directly admitted to a CSC, in line with published results. These findings should encourage its wider use in bridging therapy. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that tenecteplase within 270 minutes of LVO-AIS increases the probability of functional independence.
Authors: Aristeidis H Katsanos; Klearchos Psychogios; Guillaume Turc; Simona Sacco; Diana Aguiar de Sousa; Gian Marco De Marchis; Lina Palaiodimou; Dimitrios K Filippou; Niaz Ahmed; Amrou Sarraj; Bijoy K Menon; Georgios Tsivgoulis Journal: JAMA Netw Open Date: 2022-03-01